Episode Details

This episode builds a real framework for chronic pain by connecting two worlds that rarely get stitched together: (1) a mechanistic review arguing that mitochondrial dysfunction drives pain chronification, and (2) a systematic review of randomized clinical trials on photobiomodulation (PBM) — red/near-infrared light therapy — for chronic pain. Dr. Mike Belkowski explains why chronic pain is a bioenergetic + redox + immune signaling loop (ATP instability, mitochondrial ROS, calcium overload, neuroinflammation, and quality-control failure), then maps where PBM appears to help most in humans (especially fibromyalgia and peripheral neuropathies) while being honest about the biggest limitation: protocol variability. The punchline is practical and responsible: PBM isn’t a stand-alone magic fix — it’s best viewed as a mitochondria-targeted module inside a larger systems strategy.

(Educational content only, not medical advice.)

-

Articles Discussed in Episode:

Mitochondrial Dysfunction as a Driver of Chronic Pain: New Insights and Therapeutic Prospects

Photobiomodulation in chronic pain: a systematic review of randomized clinical trials

-

Key Quotes From Dr. Mike:

“Chronic pain is a bioenergetic problem…”

“What makes chronic pain chronic is that the pain system changes.”

“Pain transmission is expensive. Every action potential costs energy.”

“PBM… may be one of the cleanest real-world tests of a mitochondria-first pain model.”

“PBM should be seen as a module inside a larger system strategy, not a magic stand-alone fix.”

-

Key Points

• Chronic pain persists because the pain system changes: sensitization + amplification (“gain knob” turned up).

• Pain transmission is energy expensive; mitochondrial strain makes neurons hyperexcitable.

• The chronification loop: ATP instability → ROS amplification → calcium dysregulation/MPTP risk → mtDAMPs → NLRP3 + cytokines → glial amplification → more excitability → more mitochondrial damage.

• Mitochondrial quality control fails in chronic pain: mitophagy ↓, biogenesis ↓ (PGC-1α/NRF1/TFAM), dynamics skew (DRP1), transport disrupted.

• PBM is a strong real-world test because it’s fundamentally a mitochondria-influencing signal.

• RCT review (2015–2025) finds PBM often reduces pain, most consistently in fibromyalgia and peripheral neuropathies, with low adverse events.

• The limiting factor is heterogeneity: wavelengths, dose, frequency, devices, outcome measures, and follow-up windows vary widely.

• Responsible take: PBM is best viewed as a module inside a larger system strategy, not a stand-alone fix.

• Timing matters: pain chronification is a trajectory; earlier intervention may prevent “lock-in,” later intervention typically requires stacked strategies.

-

Episode timeline